ACLX קצב צמיחת רווח למניה בשנה הנוכחית Arcellx Therapeutics

Amidst the fierce competition for leadership in cell therapy, the GURU.Markets terminal chart for Arcellx (ACLX) shows earnings per share growth compared to last year, where the 14.70 metric confirms the current level. This price action reflects the success of myeloma treatment trials, while the operating model relies on outsourcing CAR-T drug production to certified plants.

This indicator tracks the percentage change in net income per share over a twelve-month period, allowing for an assessment of business scaling rates prior to the publication of final reports. By analyzing the annual dynamics of net income per share, an investor can observe the capital burn rate on R&D, which is critical for Arcellx (ACLX) due to the absence of commercial sales and the high risks associated with the development of CAR-T therapy.